|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||65.07 - 65.70|
|52 Week Range||58.29 - 66.80|
|PE Ratio (TTM)||35.26|
|Earnings Date||Oct 27, 2017|
|Dividend & Yield||1.88 (2.85%)|
|1y Target Est||70.11|
Apple, UnitedHealth, Walmart, and Merck led the losers among the Dow 30 stocks on Friday.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA® , the company’s anti-PD-1 therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test, with ...
Bernstein sees opportunity in a buyout target.